Description
Alpelisib, sold under the brand name Piqray, is a medication sold by Novartis and used to treat certain types of breast cancer. It is used together with fulvestrant.
In the European Union alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.